tolrestat tolrestat tolrestat (inn) (ay-27773) is an aldose reductase inhibitor which was approved for the control of certain diabetic complications. tolrestatclinical dataatc codea10xa01 (who) legal statuslegal status withdrawn from market identifiers iupac name n--n-methylglycine cas number82964-04-3 ypubchem cid53359iuphar/bps7404chemspider48194 nunii0t93lg5nmkkeggd02323 ychemblchembl436 ncomptox dashboard (epa)dtxsid6048834 chemical and physical dataformulac16h14f3no3smolar mass357.35 g·mol−13d model (jsmol)interactive image smiles cn(cc(=o)o)c(=s)c1=cc=cc2=c1c=cc(=c2c(f)(f)f)oc inchi inchi=1s/c16h14f3no3s/c1-20(8-13(21)22)15(24)11-5-3-4-10-9(11)6-7-12(23-2)14(10)16(17,18)19/h3-7h,8h2,1-2h3,(h,21,22) nkey:lubhdinqxihvls-uhfffaoysa-n n ny (what is this?) (verify) while it was approved for marketed in several countries, it failed a phase iii trial in the u.s. due to toxicity and never received fda approval. it was discontinued by wyeth in 1997 because of the risk of severe liver toxicity and death. it was sold under the tradename alredase.